Kingswood Acquisition Corp. (KWAC) Signs LOI with Wentworth Management Services
by Nicholas Alan Clayton on 2022-05-13 at 9:57am

Kingswood (NASDAQ:KWAC) announced this morning that it has entered into a non-binding letter of intent (LOI) to combine with broker dealer service platform Wentworth ahead of an extension vote.

Wentworth describes itself as a “special purpose vehicle to acquire and hold interests in broker dealers” with a long-hold strategy meant to capture economies of scale to serve financial institutions and advisors. It currently has about 1,500 advisors on its network with $20 billion in assets under management.

Their approach is to allow smaller broker dealer shops options for exiting or recapitalizing their businesses while bringing them into Wentworth’s wider enterprise software network. This, in turn gives smaller firms access to retail capital markets and alternative investment products not normally available to wire-house advisors.

Little else is disclosed about Wentworth either in the parties’ press release or Wentworth’s website, and the two sides could walk away with nothing further being signed. In fact, because Kingswood has an extension vote set for five days from now on May 18, this news is a “teaser” in the classic sense. Additionally, because this deal is not at the “definitive agreement” stage, just a non-binding LOI, we at SPACInsider, do not considered this deal “announced”. As such, it will remain in the “Searching” category.

Nonetheless, the press release notes that the parties aim to sign a definitive agreement before the end of the quarter with a closing expected in the third quarter of 2022.

Kingswood likely hopes that the prospect of a specific deal will keep a few more shareholders around at it’s vote to at least see and hear more. The SPAC does not intend to make an additional contribution to its trust so news such as this is usually dropped to create interest in an environment of high redemptions.

Overall, SPACs that are searching or working on a still-pending business combination have seen an average of 47.4% of shares redeemed at extension votes since the start of the year. For now, Kingswood is trading even with its pro-rata trust value of $10.25.

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved